Patient Guide: A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 21 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT07064122
Status: 🟢 Enrolling Now
Condition: Haematologic Neoplasms
Phase: PHASE1

Where You Can Participate

This study is available at 21 locations across the country.

Top locations include:
  • • Miami, Florida
  • • Tampa, Florida
  • • Houston, Texas
  • • And 18 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) - Join Clinical Trial NCTNCT07064122

How to Join This Clinical Trial - NCTNCT07064122

Learn how to participate in this PHASE1 trial studying an investigational therapy for Haematologic Neoplasms. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Haematologic Neoplasms. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Haematologic Neoplasms
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT07064122 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 21 locations. Find a study site near you:

Clinical Research Site

Miami, Florida 33136 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Tampa, Florida 33612 - United States

Status: RECRUITING

Clinical Research Site

Houston, Texas 77030 - United States

Status: NOT_YET_RECRUITING

Clinical Research Site

Heidelberg, 3084 - Australia

Status: NOT_YET_RECRUITING

Clinical Research Site

Melbourne, 3000 - Australia

Status: RECRUITING

Clinical Research Site

Shinagawa-ku, 141-0022 - Japan

Status: RECRUITING

Clinical Research Site

Yoshida-gun, 910-1193 - Japan

Status: RECRUITING

Clinical Research Site

Seoul, 05505 - South Korea

Status: WITHDRAWN

Clinical Research Site

Seoul, 3722 - South Korea

Status: WITHDRAWN

Clinical Research Site

Barcelona, 08035 - Spain

Status: RECRUITING

And 11 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for Haematologic Neoplasms:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships